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1. Introduction 
Neural tube defects (NTDs) are complex congenital anomalies. Spina bifida and anencephaly 
which arise from failure of closure of the neural tube during embryogenesis are the most 
common forms of NTDs. While anencephaly is a letal malformation, spina bifida is a common 
birth defect in which patients can suffer from a multitude of potential medical and surgical 
morbidities and increased risk of mortality throughout their life. The incidence and prevalence 
of NTDs varies in different parts of the world [1]. This is attributable to many factors 
including; geographic region, maternal age, obesity, ethnicity and socioeconomic status of the 
parents. However a declining trend has been seen in many countries. This in part may be 
explained by the availability of prenatal diagnosis, folic acid supplementation 
recommendations, folic acid food fortification initiatives and selective termination. Prevention 
of NTDs presents a complex problem as the underlying aetiologies of NTDs are an interplay of 
genetic, environmental and nutritional factors. Folate deficiency explains approximately 72% 
of NTDs cases and this chapter will primarily address the role of folic acid supplementation 
for the prevention of NTDs [2]. However, it is necessary to briefly review the metabolism of 
folate to understand how these prevention strategies were developed.  
2. An overview of folate metabolism 
Dietary folate polyglutamates need to be converted to monoglutamates before they can be 
absorbed. In the jejunum, polyglutamates are converted to monoglutamates by the enzyme  
-glutamyl hydrolyase prior to their absorption in the intestine. During absorption in the 
jejunum, the different monoglutamyl folates are converted to 5-methyltetrahydrofolate (5-
MeTHF). 5-MeTHF is the principal circulating folate and is transported across the plasma 
membranes of cells and thus the principal form by which tissues are supplied with folate. 
Within cells, folate is involved in methylation reactions where it can either donate one 
carbon units for purine and thymidine synthesis or accept one carbon units from amino 
acids. There are three principal enzymes involved in these methylation reactions. 
Methylenetetrahydrofolate reductase (MTHFR) competes with thymidylate reductase (TS) 
and methylenetetrahydrofolate dehydrogenase (MTHFD) for one carbon units. MTHFR is 
controlled by S-adenosylmethinione. 5-MeTHF donates a methyl group via methionine 
synthase to homocysteine using Vitamin B12 as a co-factor to produce S - 
adenosylmethinione [3]. Homocysteine will accumulate when there are depleted amounts of 
folate or vitamin B12. S-adenosylmethinione is a key donor in the methylation of DNA, 
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proteins and lipids. It is also essential in the metabolism of certain neurotransmitters. This 
outlines the importance of folate metabolism in cellular function especially in rapidly 
dividing cells i.e. periods of rapid growth. It is here we see the importance of folate 
metabolism in the aetiology of NTDs.  
3. Genetics: Variations in folate metabolism 
Normal folate levels with high homocysteine levels have been observed in women who 
have delivered children with NTDs [4]. This is an indicator that there must be other factors 
contributing to the aetiology of NTDs. Several genes coding for folate dependent enzymes 
have been examined for mutations that could account for NTDs. One gene that codes for a 
folate dependent enzyme is C677T polymorphism of 5,10 methylenetetrahydrofolate 
reductase (MTHFR). The function of MTHFR is to regulate production of 5-MeTHF, the 
main plasma form of the vitamin. This thermolabile variant is associated with decreased 
enzyme activity [5]. The C667T thermolabile variant gene was observed in 18% of spina 
bifida patients versus 6% of a controlled group in a study carried out by Shields et al in 
Ireland [6]. Several other studies confirmed the increased risk of NTDs in the offspring of 
women with this variant gene. The major implication of this finding is that these are a subset 
of women who may have increased folate requirements [7]. Although other mutations of the 
MTHFR gene have been identified, along with mutations in other key genes encoding for 
enzymes used in folate metabolism none have been implicated yet as contributing to cases 
of NTDs [8]. 
4. Environmental 
As described earlier the incidence of NTDs can vary with geography, socioeconomic status 
of the parents and there is a seasonal variation. Discordance in monozygotic twinning has 
also been reported in NTDs. This suggests that environmental factors may contribute to the 
aetiology of NTDs. A whole host of physical, chemical and infectious agents have been 
suggested as possible teratogens including; solvents, anaesthetics agents, X-radiation, 
viruses and paints [9]. One physical agent, hyperthermia has been investigated as a possible 
teratogen and a meta-analysis by Moretti et al in 2005 showed that maternal hyperthermia 
during critical periods of neural tube development is associated with an increased incidence 
of NTDs (OR 1.95) [10]. Of course one cannot forget the possibility of susceptible gene-
environment interactions which could help explain the geographical and seasonal variations 
seen in the incidence of NTDs. 
5. Nutritional 
Folic Acid supplementation had been shown to prevent NTDs. There had been an explosion 
of scientific and clinical data since the first seminal work by Smithsells et al more than thirty 
years ago[11]. The United Kingdom Medical Research Council Trial and the Hungarian 
Periconceptional folic acid supplementation randomised control trial in the early nineties 
outlined how folic acid supplementation could decrease the occurrence of NTD by 50-70% 
[2, 12]. This led to universal recommendations of periconceptional folic acid 
supplementation. A recent meta-analysis by the Cochrane collaboration identified five trials 
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which examined the prevalence of NTDs in women receiving folic acid supplementation, 
those receiving folic acid had a significantly reduced risk of having baby with a NTDs (risk 
ratio 0.28 95% confidence intervals (CI) 0.15 to 0.52) [13]. Indeed the evidence from these five 
trials is so overwhelmingly in favour of folic acid supplementation there has been a paucity 
of supporting trials since the year 2000. The recommendations are to take 400μg of folic acid 
daily (either from dietary sources or supplements) for at least one month before conception 
(World Health Organisation). This dosing regimen has been largely based on the association 
between maternal red cell folate (RCF) levels and the risk of NTDs.  
6. Red cell folate and serum folate and its relationship to NTD 
Irish researchers have made substantial contributions to the understanding of NTD 
epidemiology. In a large case-control study based on over 56,000 women attending the 
maternity hospitals in Dublin from 1986 to 1990, the folate and vitamin B12 levels of blood 
samples taken at the first ante-natal visit were noted as independent risk factors for neural 
tube defect [14]. Later, data representing the blood folate concentrations of NTDs cases (n = 84) 
and selected controls (n = 266) was used to calculate the degrees of risk of an NTDs birth [15]. 
Cases and controls were similar with regard to maternal age. All controls were representative 
of normal births. The red cell folate (RCF) level in early pregnancy emerged as a premier 
indicator of such risk. The overall NTDs rate was 1.9/1000 births in this study. They showed 
that the risk of NTDs is associated with RCF levels in a continuous dose-response relationship. 
The risk is reduced as RCF levels increase. With a RCF level of <150μg/l the risk of NTD is 
6.6/1000 but if the RCF level is increased beyond 400μg/l the risk falls to 0.8/1000. The RCF 
levels can be increased over a 6 month period with doses of 400μg of folic acid which can 
reduce the risk of NTDs by 47% [15]. This dose is also considered safe. However, in the context 
of food fortification programmes it may be worth reviewing this recommendation. There is no 
consensus on the minimal effective dose of folic acid. Table 1 shows the distribution of RCF in 
cases and controls and NTDs risk in each category.  
RED CELL FOLATE ng/mL RISK OF NTD PER 1000 BIRTHS
0-149 6.6
150-199 3.2
200-299 2.3
300-399 1.6
>400 0.8
Table 1. Overall risk of a neural tube defect pregnancy associated with low red cell folate 
status. 
The largely European drive for improved periconceptional education and folic acid 
supplementation has not seen the reduction in NTDs predicted. A large international cohort 
study involving ten countries and covering more than 13 million births concluded that 
recommendations alone did not improve trends of incidence of NTDs[16]. Countries which 
had implemented food fortification programmes were excluded from this study. This 
underlines the entire problem with the prevention of NTDs. For folic acid to work it must be 
taken within the first four weeks of pregnancy, before the woman knows she is pregnant!  
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7. Food fortification 
Many countries have identified new strategies to increase serum folate levels in women of 
reproductive age. In the US, Canada, South Africa and Chile they have adopted national 
floor fortification policies and have seen a substantial decrease in the numbers of new cases 
of NTDs. In March 1996, the U.S. Food and Drug Administration (FDA) issued a final rule, 
effective January 1998, that required all enriched cereal-grain products (flour, rice, breads, 
rolls and buns, pasta, corn grits, corn meal, farina, macaroni and noodle products) to be 
fortified with folic acid 0.14mg folic acid /100g flour and 0.24 mg/100g pasta in addition to 
the iron, thiamin, riboflavin and niacin already added to these enriched cereal-grain 
products. Mandatory food fortification has been the solution to NTDs in the USA, and has 
had a dramatic effect on the folate status there [17, 18]. Further evidence to support the 
process of food fortification has emerged. Jacques et al. looked at blood folate status in a 
control group before fortification and a group after fortification. They found that the mean 
plasma folate (for non-users of B-vitamin supplementation) increased from 4.6μg/L before 
fortification to 10μg/L after folic acid fortification. They also noted that with fortification 
there was a decrease in the prevalence of high homocyteine levels from 18.7 to 9.8% [19].The 
U.S. Centres for Disease Control and Prevention reported that there has been a three-fold 
increase in the serum folate status of women aged 15-44 years who did not use 
supplements[18]. Another report published in 2000 looked at data collected from the 
Framingham Offspring Cohort Study. It was found that among non-supplement users, folic 
acid intake increased by a mean of 190μg/day and total folate intake increased by a mean of 
323μg/day dietary folate equivalents in the exposed participants[20]. In Canada a 
mandatory fortification policy was also adopted; specific cereal grain products had to be 
fortified with folic acid at a level of 0.15mg/100g by November 1st 1998. Persad et al looked 
to see if folic acid supplementation or fortification changed the annual incidence of open 
NTDs in Nova Scotia. The study looked at the total number of births and stillbirths with 
NTDs and the number of terminated pregnancies affected with NTDs from perinatal and 
fetal anomaly databases. They reported that the incidence of open NTDs (spina bifida, 
anencephaly, encephaloceles) decreased by 54% after the Canadian fortification program 
was implemented. In 1991 to 1997 the mean annual rate was 2.58 per 1000 births and from 
1997 to 2000 was 1.17 per 1000 births [21]. De Wals et al demonstrated similar results, 
showing a decline in the prevalence of NTDs from 1.58 per 1000 pregnancies before 
fortification to 0.86 per 1000 pregnancies thereafter giving a 46% reduction (95% CI 40-51) 
[22]. Mandatory fortification has also been introduced in other countries in Central and 
South American and in the Middle East. In Chile, the addition of folic acid to wheat flour 
commenced in January 2000. A study looking at the prevalence rate of spina bifida and 
anencephaly there demonstrated a decrease in the years 2001 and 2002 [23]. The decrease 
was approximately 51% for spina bifida and 46% for anencephaly. These results showed an 
obvious benefit in folic acid fortification and do not significantly differ from those published 
from other folic acid fortified populations in Canada and the USA. The main strength of this 
paper is that termination of pregnancy is illegal in Chile and therefore the observed data is 
complete and not influenced by termination of pregnancy such as occurs in other countries. 
In the USA the level of folic acid fortification, at 140ug/gm of flour, was chosen to be 
sufficient to prevent NTDs and to provide less than 1mg/day additional folate, a limit set by 
the Institute of Medicine (IOM) in 1998. There is a concern that excessively high levels might 
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delay the diagnosis of a haematological or neurological impairment due to vitamin B12 
deficiency, which could potentially be masked by high serum folate. Food fortification 
policies in Europe have been delayed due to difficulty in determining the effective dose and 
concerns about safety. This helps explain the disparity in reduction of NTDs in Europe 
when compared to the USA and Canada [24]. An Irish study carried out in the late nineties 
indicated effectiveness and safety at a dose between 100µg and 200µg[25].  
8. The cases for high dose folic acid  
8.1 Epilepsy and Anti-Epileptic Drugs (AED) 
The association of epilepsy and NTDs is well known. The risk of a woman with epilepsy on 
AEDs of having a child affected with a NTDs is 1-2% [26]. The known anti-folate mechanism 
of action of AEDs (especially valporate and carbamazepine) would intuitively indicate a 
recommendation of folic acid supplementation and is supported by a study in Hungary 
showing that the risk of congenital abnormalities could be reduced but not eliminated by 
folic acid supplementation[27]. However, the benefits have not been clearly demonstrated 
by a large prospective study in the United Kingdom [28]. A Cochrane review on the 
effectiveness of pre-conception counselling for women with epilepsy did not outline any 
consensus on the recommended dose, which varies in different countries from 0.4µg to 
5mg[29].  
9. Obesity 
Many countries have seen a substantial rise in the prevalence of obesity in women of 
reproductive age in the last twenty years. It is an important observation and of critical value 
when interpreting the effects this may have on the observed rates of NTDs. Several studies 
have reported an increased risk of NTDs in the offspring of obese women. This risk can vary 
from no risk at all as demonstrated in one study[30] to a 3 fold increase in risk in a study by 
Shaw et al in 1996[31]. A recent meta-analysis by Rasmussen et al in 2008 identified 12 
studies (4 cohort and 8 case controls) which investigated the relationship between maternal 
obesity and the risk of NTDs[32]. The odds ratio for a NTD-affected pregnancy was 1.22 
(95% CI 0.99-1.49) for overweight women, 1.70 (95% CI 1.34-2.15) for obese women and 3.11 
(95% CI 1.75-5.46) for severely obese women. This meta-analysis controlled for confounding 
factors such as date of publication, diabetes and folic acid intake. There are three main 
hypotheses for this increased risk of NTDs in obese women. Firstly, the association of NTDs 
and the teratogenic effects of hyperglycaemia may be a possible explanation [33]. Altered 
glucose metabolism in these women leads to hyperinsulinaemia, which has been shown to 
be associated with NTDs. This is similar to the mechanisms causing the increased NTD-
affected pregnancies in diabetic patients. A second possible explanation for the association 
of obesity and NTDs is that obese women have a higher dietary requirement for folic acid. It 
is well established that higher plasma and red cell folate levels are associated with a lower 
risk of NTDs. A study carried out by Werler et al and published 1996 showed that obese 
women, specifically those greater than 70 kgs, were less responsive to the WHO 
recommended 400µg dose than women of a normal weight[34]. Further investigations of 
women with a higher BMI showed overall lower serum folate levels and advised that obese 
women should take 750µg of folic acid to reach satisfactory RCF levels[35]. The final 
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hypothesis is that these findings simply reflect that prenatal diagnosis of NTDs in women 
who are obese is limited. Therefore more NTD-affected pregnancies would result in live 
births and this more likely to be identified in the birth defects surveillance systems which 
were used to identify the cases for the meta-analysis. This factor may have led to an over 
estimation of the risk associated with maternal obesity. 
10. Conclusion 
This chapter outlines the aetiologies and strategies for preventing neural tube defects. It is 
clear from international data that we should be striving for national policies for food 
fortification programmes to effectively reduce the incidence of neural tube defects. Future 
studies focus on identifying those who may have an increased folate requirement either due 
to a genetic predisposition or co-morbidities. 
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